Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-279252 in Advanced Solid Tumors or Lymphomas
NCT03894618Phase 1Completed
- Sponsor
- Shattuck Labs
- Start
- Mar 2019
- Primary completion
- May 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of sl-279252 in melanoma, non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and 10 more, sponsored by Shattuck Labs. Primary endpoints: Safety Profile of SL-279252 and Maximum Tolerated Dose. Started Mar 2019; status: completed.
02
Drugs
sl-279252
03
Conditions
melanomanon-small cell lung cancer (NSCLC)urothelial carcinoma (UC)squamous cell carcinoma of the head and neck (HNSCC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT03894618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894618.